Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally.
No risks detected for BVS from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$13.64|
|52 Week High||US$10.74|
|52 Week Low||US$19.94|
|1 Month Change||-1.73%|
|3 Month Change||-16.17%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-28.99%|
Recent News & Updates
|BVS||US Medical Equipment||US Market|
Return vs Industry: Insufficient data to determine how BVS performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how BVS performed against the US Market.
Stable Share Price: BVS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: BVS's weekly volatility (6%) has been stable over the past year.
About the Company
Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived bone graft with growth factors, demineralized bone matrix, cancellous bone in different preparations, bioactive synthetics, collagen ceramic matrix, and bone marrow isolation systems.
Bioventus Fundamentals Summary
|BVS fundamental statistics|
Is BVS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BVS income statement (TTM)|
|Cost of Revenue||US$104.29m|
Last Reported Earnings
Jul 03, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.10|
|Net Profit Margin||-1.59%|
How did BVS perform over the long term?See historical performance and comparison
Is Bioventus undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BVS ($13.64) is trading below our estimate of fair value ($70.28)
Significantly Below Fair Value: BVS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BVS is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: BVS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BVS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BVS is overvalued based on its PB Ratio (5.5x) compared to the US Medical Equipment industry average (4.3x).
How is Bioventus forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BVS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: BVS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BVS's is expected to become profitable in the next 3 years.
Revenue vs Market: BVS's revenue (10.6% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: BVS's revenue (10.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BVS's Return on Equity is forecast to be high in 3 years time (32.3%)
How has Bioventus performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: BVS is currently unprofitable.
Growing Profit Margin: BVS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if BVS's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare BVS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BVS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (36.1%).
Return on Equity
High ROE: BVS has a negative Return on Equity (10.92%), as it is currently unprofitable.
How is Bioventus's financial position?
Financial Position Analysis
Short Term Liabilities: BVS's short term assets ($290.1M) exceed its short term liabilities ($158.2M).
Long Term Liabilities: BVS's short term assets ($290.1M) exceed its long term liabilities ($269.1M).
Debt to Equity History and Analysis
Debt Level: BVS's debt to equity ratio (82.5%) is considered high.
Reducing Debt: BVS's debt to equity ratio has reduced from 110.2% to 82.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable BVS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: BVS is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 15.1% per year.
What is Bioventus's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BVS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BVS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BVS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BVS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BVS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ken Reali (55 yo)
Mr. Kenneth M. Reali, also known as Ken, serves as Chief Executive Officer and Member of Board of Managers at Bioventus LLC April 20, 2020. Mr. Reali serves as Chief Executive Officer of Bioventus Inc. sin...
CEO Compensation Analysis
Compensation vs Market: Ken's total compensation ($USD5.46M) is above average for companies of similar size in the US market ($USD2.26M).
Compensation vs Earnings: Insufficient data to compare Ken's compensation with company performance.
Experienced Management: BVS's management team is considered experienced (4.3 years average tenure).
Experienced Board: BVS's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BVS insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: BVS only recently listed within the past 12 months.
Bioventus Inc.'s employee growth, exchange listings and data sources
- Name: Bioventus Inc.
- Ticker: BVS
- Exchange: NasdaqGS
- Founded: 2011
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: US$775.426m
- Market Cap: US$560.095m
- Shares outstanding: 56.85m
- Website: https://www.bioventus.com
Number of Employees
- Bioventus Inc.
- 4721 Emperor Boulevard
- Suite 100
- North Carolina
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/17 22:06|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.